Dapagliflozin Gains Initial FDA Approval for Teva Pharmaceuticals

On 2026-04-06, the U.S. Food and Drug Administration (FDA) announced the initial approval of Dapagliflozin, an important milestone for Teva Pharmaceuticals USA. This approval, granted under Abbreviated New Drug Application (ANDA) 211541, signifies the market entry of a generic version of the drug.

What this means

The initial FDA approval of generic Dapagliflozin by Teva Pharmaceuticals USA is expected to enhance market competition and potentially increase patient access to this medication. Generic drugs typically offer more cost-effective alternatives, which can lead to broader availability for patients requiring treatment with Dapagliflozin.

Source

The information for this approval was sourced from the U.S. Food and Drug Administration (FDA). The approval for Abbreviated New Drug Application (ANDA) 211541 was granted on 2026-04-06 and is publicly accessible on accessdata.fda.gov.